Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Exp Neurol. 2018 Nov 22;312:43–50. doi: 10.1016/j.expneurol.2018.11.006

Fig. 2.

Fig. 2.

Tacrolimus reduces the frequency of Tfh and Tregs subsets in MuSK-MG. (A) Intranuclear staining for FOXP3+ Tregs after culturing without tacrolimus (left) and 10ng/ml tacrolimus (right) for 3 days. (B) Composite data from individual MuSK-MG patients showing the frequency of Tregs in the absence of tacrolimus (left column, black) and 10ng/ml tacrolimus (right column, grey). (C) Surface staining for CXCR5+ Tfh cells after culturing without tacrolimus (left) and 10ng/ml tacrolimus (right) for 3 days. (D) Composite data from individual MuSK-MG patients showing the frequency of Tfh cells in the absence of tacrolimus (left column, black) and 10ng/ml tacrolimus (right column, grey). (E) Intranuclear staining for FOXP3+CXCR5 Tfr cells after culturing without tacrolimus (left) and 10ng/ml tacrolimus (right) for 3 days. (F) Composite data from individual MuSK-MG patients showing the frequency of Tfr cells in the absence of tacrolimus (left column, black) and 10ng/ml tacrolimus (right column, grey). Statistical significance is represented as follows: ** p≤0.01; *** p≤0.001. Results are shown from four independent experiments, analyzing a total of 15 patients.